Development of an HPLC–MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Upadhyay J, Polyzos SA, Perakakis N et al. Pharmacotherapy of Type 2 diabetes: an update. Metab. Clin. Exp. 78, 13–42 (2018).
  Medline CASGoogle Scholar
• 2 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in Type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1), 140–149 (2015).
  MedlineGoogle Scholar
• 3 Marx N, Mcguire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur. Heart J. 37(42), 3192–3200 (2016).• A strong proof to support sodium-glucose co-transporter-2 inhibitor for the reduction of cardiovascular events in diabetes mellitus patients.
  Medline CASGoogle Scholar
• 4 Avranas K, Imprialos K, Stavropoulos K et al. Sodium-glucoser cotransporter 2 inhibitors: glucose lowering against other hypoglycemic agents. Cardiovasc. Hematol. Disord. Drug Targets 18(2), 94–103 (2018).
  Medline CASGoogle Scholar
• 5 Aubry AF, Gu H, Magnier R et al. Validated LC–MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis 2(12), 2001–2009 (2010).
  CASGoogle Scholar
• 6 Dong ST, Niu HM, Wu Y et al. Plasma pharmacokinetic determination of canagliflozin and its metabolites in a Type 2 diabetic rat model by UPLC–MS/MS. Molecules 23(5), (2018).
  Google Scholar
• 7 Iqbal M, Ezzeldin E, Al-Rashood KA, Asiri YA, Rezk NL. Rapid determination of janagliflozin in rat plasma by UHPLC–MS/MS using negative ionization mode to avoid adduct-ions formation. Talanta 132, 29–36 (2015).
  Medline CASGoogle Scholar
• 8 Ji QC, Xu X, Ma E et al. Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies. Anal. Chem. 87(6), 3247–3254 (2015).
  Medline CASGoogle Scholar
• 9 Kobuchi S, Ito Y, Yano K, Sakaeda T. A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1000, 22–28 (2015).
  Medline CASGoogle Scholar
• 10 Kobuchi S, Matsuno M, Fukuda E, Ito Y, Sakaeda T. Development and validation of an LC–MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1027, 227–233 (2016).
  Medline CASGoogle Scholar
• 11 Kobuchi S, Matsuno M, Kawamoto M et al. A simple and rapid LC–MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study. Bioanalysis 9(2), 163–171 (2017).
  CASGoogle Scholar
• 12 Kobuchi S, Yano K, Ito Y, Sakaeda T. A validated LC–MS/MS method for the determination of janagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Biomed. Chromatogr. doi:10.1002/bmc.3720 (2016).
  MedlineGoogle Scholar
• 13 US FDA. Guidance for Industry: Bioanalytical Method Validation (2001). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
  Google Scholar
• 14 China Food and Drug Administration (2015). http://www.sda.gov.cn/gsz05106/08.pdf.
  Google Scholar
• 15 US FDA. Draft Guidance for Industry in Bioanalytical Method Validation (2013). https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
  Google Scholar
• 16 Niessen WM. Fragmentation of toxicologically relevant drugs in negative-ion liquid chromatography–tandem mass spectrometry. Mass Spectrom. Rev. 31(6), 626–665 (2012).•• Excellent review summarized the drug fragmentation in ESI negative mode.
  Medline CASGoogle Scholar
• 17 Wang L, Duan C, Wu D, Guan Y. Quantification of endogenous brassinosteroids in sub-gram plant tissues by in-line matrix solid-phase dispersion–tandem solid phase extraction coupled with high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1359, 44–51 (2014).•• Excellent example for method development of bioanalytical assays using HPLC–MS/MS coupled with the solid-phase extraction procedure.
  Google Scholar
• 18 Boyaci E, Rodriguez-Lafuente A, Gorynski K et al. Sample preparation with solid phase microextraction and exhaustive extraction approaches: Comparison for challenging cases. Anal. Chim. Acta 873, 14–30 (2015).•• Good summary about the main advantages and limitations of the different sample preparation approaches.
  Medline CASGoogle Scholar
• 19 Liu D, Ma X, Liu Y et al. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. Eur. J. Pharm. Sci. 89, 73–82 (2016).•• A good example to predict PK concentrations and to support the range setting of the bioanalytical methods.
  Medline CASGoogle Scholar
• 20 China Food and Drug Administration. Drug Clinical Trial Registration and Information Publicity Platform (CTR20170535) (May 31st 2017). http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlistdetail.• The corresponding details of janagliflozin clinical single dose ascending trial.
  Google Scholar